For frail patients with cardiac co-morbidities and relapsed CLL with high cytogenetic risk, what are some considerations for using continuous acalabrutinib over fixed duration therapies such as venetoclax/rituximab?

Continuous acalabrutinib has relatively low incidence of significant AE and does not require multiple prolonged infusion visits which is very appealing for frail patients. As well, available data would suggest that those with TP53 abnormalities (high genetic risk) do similarly to those without this ...

This is a complicated question and I evaluate each patient individually. I worry more about patients with reduced cardiac function on BTK inhibitors than I do those with pre-existing atrial fibrillation, and if they are on anticoagulation as well, that is a further concern. If the patient has reduce...